|
|
News Breaks | | | | April 11, 2012 | | 06:55 EDT |  | SHPGY, SHPGY, SHPGY, INFI, INFI, INFI, AMGN, AMGN, AMGN, LXRX, LXRX, LXRX, ZGNX, ZGNX, ZGNX, EPCT, EPCT, EPCT, MRK, MRK, MRK, BIIB, BIIB, BIIB, AZN, AZN, AZN, GSK, GSK, GSK, CELG, CELG, CELG, KFY, KFY, KFY | Elsevier Business Intelligence to host a conference
Pharmaceutical Strategic Outlook: Biopharma Strategic Dealmaking Conference is being held in New York on April 11-13 with pre-conference workshops being held on April 11 and the conference starting on April 12 at 8 am. | |
|
News For KFY;CELG;GSK;AZN;BIIB;MRK;EPCT;ZGNX;LXRX;AMGN;INFI;SHPGY From The Last 14 Days Check below for free stories on KFY;CELG;GSK;AZN;BIIB;MRK;EPCT;ZGNX;LXRX;AMGN;INFI;SHPGY the last two weeks. |
|
|
| May 22, 2013 | | 18:52 EDT |  | MRK | On The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 13.4% after reporting second quarter earnings that beat expectations and guiding third quarter and full-year earnings above estimates... Pacific Sunwear (PSUN), up 14.3%. ALSO HIGHER: Merck (MRK), up 0.2% after an FDA advisory panel voted 13-3 in support of the safety of initial doses of its insomnia drug suvorexant. DOWN AFTER EARNINGS: DryShips (DRYS), down 4.7%. ALSO LOWER: Apricus Biosciences (APRI), down 11.5% after filing to sell an ungiven amount of stock... NCI Building Systems (NCS) after being replaced by Cynosure (CYNO) in the S&P 600 as of May 31. | | | 18:32 EDT | | MRK | Merck's suvorexant for insomnia reviewed by FDA advisory committee
 Subscribe for More Information | | | 18:06 EDT |  | MRK | Merck insomnia drug gets FDA panel backing, WSJ reports
Merck's insomnia drug suvorexant received a favorable 13-3 vote from an FDA panel on the drug's two proposed starting doses, with the panel splitting the vote on the safety of higher doses, reports the Wall Street Journal. Reference Link | | | 16:16 EDT | | MRK | FDA panel votes 13-3 that Merck insomnia drug safe in low doses, Bloomberg says
Subscribe for More Information | | | 16:00 EDT |  | MRK | Options Update; May 22, 2013
Subscribe for More Information | | | 14:52 EDT | | MRK | FDA panel says Merck insomnia drug effective as sleep aid, Bloomberg reports
Subscribe for More Information | | | 09:39 EDT | | MRK | Active equity option families trading
Subscribe for More Information | | | 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information | | | 08:25 EDT | | GSK | GlaxoSmithKline awarded up to $200M by U.S. to develop new antibiotics
Subscribe for More Information | | | 07:45 EDT | | MRK | FDA Peripheral & Central Nervous System Drugs Advisory Committee holds a meeting
Subscribe for More Information | | | | May 21, 2013 | | 18:56 EDT | | MRK | On The Fly: After Hours Movers
Subscribe for More Information | | | 17:03 EDT | | MRK | Merck announces $5B share repurchase
Subscribe for More Information | | | 17:01 EDT | | MRK | Merck announces $5B accelerated share repurchase
Subscribe for More Information | | | 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). | | | 07:44 EDT | | MRK, GSK | Sachs Associates to host a forum
Subscribe for More Information | | | 07:24 EDT | | BIIB | Global Health Care to host a conference
Subscribe for More Information | | | 07:07 EDT |  | GSK | Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray
Subscribe for More Information | | | 06:12 EDT | | KFY | Executive recruiters say business is improving, Bloomberg reports
Business at executive-recruitment companies is improving, boosted by increasing confidence among corporate leaders and a stabilization in hiring for senior positions in the financial-services industry, reports Bloomberg. Heidrick & Struggles International and Russell Reynolds Associates say they see some increase in demand, a trend that was echoed in a recent survey of consultants by William Blair & Co., an independent investment firm.Reference Link | | | 05:44 EDT | | BIIB | Biogen submits application to FDA for approval of Plegridy in RMS
Subscribe for More Information | | | May 20, 2013 | | 17:49 EDT | | MRK | Merck sleep drug effective, dosages questioned, WSJ reports
Subscribe for More Information | | |
|
|
|
|
|
|
